Αρχική World News Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk... World News Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN Από Ogkologos - 9 Ιανουαρίου, 2026 590 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the GORTEC 2018-01 NIVOPOST-OP study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR Cure Probability Models for Evaluation of Patients with a Previous Cancer... 26 Οκτωβρίου, 2021 A Subset of Patients with NSCLC Respond Poorly to the COVID-19... 4 Ιουλίου, 2022 The 10-year cancer plan: is improving cancer survival still a priority... 8 Δεκεμβρίου, 2022 First Study to Demonstrate that PD1 Immune Checkpoint Blockade May Yield... 4 Δεκεμβρίου, 2023 Φόρτωση περισσοτέρων HOT NEWS Cómo prepararse para su exploración por TEP-TC Coronavírus e COVID-19: o que as pessoas com câncer precisam saber Opinion: The Government should not be choosing between investing in staff... Making a startup out of a scientist